# ImmunoGen, Inc.

ImmunoGen, Inc. is a company headquartered in Waltham, MA, United States.

## Company overview

- **Legal name:** ImmunoGen, Inc.
- **Former names in filing history:** IMMUNOGEN INC (1994-02-14 to 2019-08-05)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Waltham, MA, United States
- **Incorporated in:** MA
- **Fiscal year end:** December 31
- **SEC CIK:** 0000855654

## About

ImmunoGen, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000855654, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-03-01, it reported annual revenue of USD 108,782,000; net income of USD -222,929,000; total assets of USD 348,936,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $108.8M (USD 108,782,000)
- **Net income:** -$222.9M (USD -222,929,000)
- **Total assets:** $348.9M (USD 348,936,000)
- **Cash and equivalents:** $275.1M (USD 275,138,000)
- **Operating cash flow:** -$229.8M (USD -229,802,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $69.9M (USD 69,856,000)
- **Net income:** -$139.3M (USD -139,303,000)
- **Total assets:** $525.8M (USD 525,765,000)
- **Cash and equivalents:** $478.8M (USD 478,750,000)
- **Operating cash flow:** -$169.4M (USD -169,416,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $132.3M (USD 132,299,000)
- **Net income:** -$44.4M (USD -44,372,000)
- **Total assets:** $355.1M (USD 355,072,000)
- **Cash and equivalents:** $293.9M (USD 293,856,000)
- **Operating cash flow:** -$78.6M (USD -78,620,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $82.3M (USD 82,271,000)
- **Net income:** -$104.1M (USD -104,133,000)
- **Total assets:** $235.3M (USD 235,262,000)
- **Cash and equivalents:** $176.2M (USD 176,225,000)
- **Operating cash flow:** -$88.4M (USD -88,367,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2024-02-12 — period 2024-02-12 — FORM 8-K
- Form 8-K — filed 2024-02-08 — period 2024-02-07 — FORM 8-K
- Form 8-K — filed 2024-01-31 — period 2024-01-31 — FORM 8-K
- Form 8-K — filed 2024-01-29 — period 2024-01-29 — FORM 8-K
- Form 8-K — filed 2024-01-24 — period 2024-01-24 — FORM 8-K
- Form 8-K — filed 2024-01-08 — period 2024-01-08 — FORM 8-K
- Form 8-K — filed 2023-11-30 — period 2023-11-30 — FORM 8-K
- Form 10-Q — filed 2023-11-02 — period 2023-09-30 — 10-Q
- Form 8-K — filed 2023-11-02 — period 2023-11-02 — 8-K
- Form 8-K — filed 2023-09-18 — period 2023-09-18 — 8-K
- Form 10-Q — filed 2023-07-31 — period 2023-06-30 — 10-Q
- Form 8-K — filed 2023-07-31 — period 2023-07-31 — 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/immunogen-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology